Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2017
  • Case
  • HBS Case Collection

Bayer AG: Bidding to Win Merck's OTC Business

By: Benjamin C. Esty, Marc Baaij and Arjen Mulder
  • Format:Print
  • | Language:English
  • | Pages:21
ShareBar

Abstract

Shortly after submitting their best and final offer to acquire Merck's Consumer Care Division (a collection of "over-the-counter" (OTC) products with sales totaling $2 billion), the Bayer M&A team was given a chance to revise their bid because another potential acquirer—likely Reckitt-Benckiser, a UK-based company that had outbid them in a few prior acquisition auctions—had submitted a last-minute offer to Merck. Frank Rittgen (head of M&A) and Werner Baumann (CFO) have to decide whether to increase the cash portion of their $14.2 billion offer and/or amend the terms of a proposed joint venture (JV) with Merck involving cardiovascular drugs that had been included in their offer as a way to "sweeten" the deal. Under the current terms of the proposed JV, Merck would pay Bayer $1 billion upfront for access to their pipeline of drugs and could pay up to another $1.2 billion in contingent payments based on actual sales. Alternatively, the Bayer team could hold fast on both fronts and let their final bid stand. With only an hour to make a decision regarding one of the industry's "transformational assets," the Bayer team had to move quickly and carefully as they were determined not to overpay for the asset.

Keywords

Acquisition; Bidding Strategy; Valuing Synergies; Negotiations; Corporate Strategy; Business Unit Strategy; Bidding Process; Discounted Cash Flow; Cross-border M&A; Tax Shields; Valuation; Competitive Strategy; Auctions; Bids and Bidding; Germany; United States; United Kingdom

Citation

Esty, Benjamin C., Marc Baaij, and Arjen Mulder. "Bayer AG: Bidding to Win Merck's OTC Business." Harvard Business School Case 217-021, January 2017.
  • Educators
  • Purchase

About The Author

Benjamin C. Esty

Finance
→More Publications

Related Work

    • January 2017
    • Faculty Research

    Bayer AG: Bidding to Win Merck's OTC Business

    By: Benjamin C. Esty, Marc Baaij and Arjen Mulder
Related Work
  • Bayer AG: Bidding to Win Merck's OTC Business By: Benjamin C. Esty, Marc Baaij and Arjen Mulder
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College